BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18823306)

  • 1. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
    Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
    Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data.
    Silva MR; de Oliveira BM; Viana MB; Murao M; Romanha AJ
    Ther Drug Monit; 2008 Dec; 30(6):700-4. PubMed ID: 19057372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
    Fakhoury M; Andreu-Gallien J; Mahr A; Medard Y; Azougagh S; Vilmer E; Jacqz-Aigrain E
    J Clin Pharm Ther; 2007 Dec; 32(6):633-9. PubMed ID: 18021342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
    Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
    Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia.
    Kapoor G; Sinha R; Naithani R; Chandgothia M
    Leuk Res; 2010 Aug; 34(8):1023-6. PubMed ID: 20153897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
    Melachuri S; Gandrud L; Bostrom B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
    Donnan JR; Ungar WJ; Mathews M; Hancock-Howard RL; Rahman P
    Pediatr Blood Cancer; 2011 Aug; 57(2):231-9. PubMed ID: 21344614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
    Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
    Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
    Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia.
    Albayrak M; Konyssova U; Kaya Z; Gursel T; Guntekin S; Percin EF; Kocak U
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1155-9. PubMed ID: 21400026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.
    Milek M; Karas Kuzelicki N; Smid A; Mlinaric-Rascan I
    Biochem Pharmacol; 2009 Jun; 77(12):1845-53. PubMed ID: 19428339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
    Karas-Kuzelicki N; Mlinaric-Rascan I
    Pharmacogenomics; 2009 Aug; 10(8):1309-22. PubMed ID: 19663675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
    Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
    Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
    Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
    J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
    Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
    Brackett J; Schafer ES; Leung DH; Bernhardt MB
    Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.